The clinical program has been designed to cover the essential aspects of the technology that provides the data needed to use the IMBG in a reliable way in clinical practice. It is very important to consider that the IMBG will not directly guide physician prescription. This means that the tool does not ambition to tell the doctor what medicine should be used; we offer efficacy/potency information to be added to other variables, which altogether combined, will drive the clinical decision.

Clinical decisions will have always to be made taking into account other important patient variables (like immunological patients´ profile, baseline disease activity, clinical evolution and treatment side effects) to help physicians to make more precise therapeutic decisions.